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Iron is an essential element for virtually all-living organ-
isms. It is required as a cofactor for a multitude of pro-
teins of diverse biological function. Iron plays a central
role in the formation of hemoglobin and myoglobin and
in many vital biochemical pathways and enzyme systems
including energy metabolism, neurotransmitter produc-
tion, collagen formation and immune system function.
As a transition metal, iron also has useful ligand-bind-
ing and redox properties. At the same time, iron poses
enormous problems because of the easy inter-conversion
of Fe(II) and Fe(III), the very property that makes it
attractive for biological redox processes (1). The reduced
iron, Fe(II) can produce highly reactive hydroxyl and
lipid radicals, which can damage lipid membranes,
nucleic acids and proteins. In the million years of evolu-
tion, nature has not developed a pathway for excretion
of iron in humans, so the body concentration of iron
can only be regulated by absorption to match losses of
iron.
Under normal circumstances 1–2 mg of iron enters
and leaves the body each day. In the body, iron is
distributed in three pools – functional, storage and
transport iron. The absorbed iron circulates in the
plasma bound to transferrin (Tf) (transport iron) and
the excess iron gets stored in the parenchymal cells of
the liver and reticuloendothelial macrophages as ferritin
(storage iron). About 0.1% of total body iron is circu-
lating bound to Tf. Nearly 80% of iron is utilized for
hemoglobin synthesis in the bone marrow. Approxi-
mately 10–15% is present in muscle fibers (myoglobin)
and in other tissues as enzymes and cytochromes (func-
tional iron).
Homeostatic mechanisms regulating the absorption,
transport, storage and mobilization of cellular iron are
therefore of critical importance in iron metabolism, and
a rich biology and chemistry underlie all of these mecha-
nisms. The last decade has seen a rapid advancement of
knowledge in iron metabolism. Modern techniques in
molecular biology and biochemistry are giving new
insights through the identification and characterization
of proteins involved in iron homeostasis. This review
focuses on the current developments in the understand-
ing of iron homeostasis and the delicate mechanisms
involved in the regulation of iron in the body.
Abstract
Although iron is a relatively abundant element in the universe, it is estimated that more than 2 billion peo-
ple worldwide suffer from iron deficiency anemia. Iron deficiency results in impaired production of iron-
containing proteins, the most prominent of which is hemoglobin. Cellular iron deficiency inhibits cell
growth and subsequently leads to cell death. Hemochromatosis, an inherited disorder results in dispropor-
tionate absorption of iron and the extra iron builds up in tissues resulting in organ damage. As both iron
deficiency and iron overload have adverse effects, cellular and systemic iron homeostasis is critically
important. Recent advances in the field of iron metabolism have led to newer understanding of the path-
ways involved in iron homeostasis and the diseases which arise from alteration in the regulators. Although
insight into this complex regulation of the proteins involved in iron homeostasis has been obtained mainly
through animal studies, it is most likely that this knowledge can be directly extrapolated to humans.
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Iron absorption
Iron absorption occurs predominantly in the apical sur-
face of the duodenum and upper jejunum. The two
forms of dietary iron namely heme and non-heme iron
are absorbed by the enterocyte non-competitively.
Heme iron is not chelated and not precipitated by
numerous constituents of the diet that render non-heme
iron difficult to-absorb. Shayegi et al. (2) have identified
a membrane protein called heme carrier protein 1 which
mediates heme uptake by cells. Once heme enters the cell,
it is opened up by heme oxygenase to release Fe2+ and
thereafter the fate of both heme and non-heme iron are
the same.
The non-heme iron mainly exists in the Fe3+ state.
The ferric iron is reduced to ferrous iron before it is
transported across the intestinal epithelium. This is
accomplished by dietary components and duodenal cyto-
chrome b reductase (Dcytb) which is highly expressed in
the brush border of enterocytes (3). Once the insoluble
Fe3+ is converted to Fe2+, it enters the mucosal phase.
Fe2+ is transported across the apical membrane into the
cell through a divalent metal transporter (DMT1).
DMT1 is expressed at the duodenal brush border where
it controls uptake of dietary iron. A pathway for Fe3+
transport has also been proposed, where it is transported
as an integrin–mobilferrin (IM) complex across the en-
terocyte. This Fe3+–IM complex combines with flavine
mono oxygenase and b2-microglobulin in the cytosol to
form paraferritin. The Fe3+ is then converted to Fe2+
by the inherent ferrireductase activity of paraferritin and
is transported out as Fe2+ by DMT1, which is also pres-
ent in the paraferritin (4).
The Fe2+ inside the cell can undergo two fates – either
it can be stored as ferritin or transported across the baso-
lateral surface into the blood stream. The mechanism by
which Fe2+ reaches the basolateral membrane is poorly
understood. The factors that decide whether iron will be
stored in the intestinal cell or transported into the plasma
are not yet clear but are being slowly understood.
The iron inside the cell is exported out of the cell by a
transport protein called ferroportin (FPN). Hephaestin, a
multicopper ferroxidase, works in concert with FPN in
the export of iron from the enterocytes (5,6). It is a
transmembrane-bound ceruloplasmin homolog highly
expressed in the intestine (7). It oxidizes Fe2+ and
enables it to be taken up by Tf. Ceruloplasmin also plays
a role in oxidation under conditions of stress (8).
Studies have shown that plant and animal ferritin can
also be absorbed in the intestine (9,10). Receptors for
lactoferrin, an iron binding protein are found in fetal en-
terocytes (11). Lactoferrin is viewed as the primary
source of iron in infants and it may be a source in adult
females also (12).
Regulation of iron absorption is complex and depends
on dietary factors, body iron stores and erythropoiesis.
The changes in the dietary iron are sensed by the villus
enterocytes and there is a rapid regulation of transport-
ers. Cells in the crypt express HFE and Tf receptor
(TfR) on the basolateral surface (13), but their exact role
in regulation of iron absorption is not clear. In addition,
regulation may be exerted by several humoral and tissue
derived factors like hepcidin and cytokines. Crosstalk
between the epithelial cells and other cells like macro-
phages, neutrophils and intra-epithelial lymphocytes also
play an important role in iron absorption. The way in
which the erythropoietic demand controls iron absorp-
tion has not been elucidated. Hepcidin levels are
decreased by high erythropoietic activity (14) and it has
been postulated that erythroid regulation of absorption
is controlled through Hepcidin. Growth differentiation
factor 15, is a member of the transforming growth factor
beta family. Recent evidence suggests that when it is over
expressed because of an expanded erythroid compart-
ment, this contributes to iron overload in thalassemia
syndromes by inhibiting hepcidin expression (15).
Transport, uptake and storage of iron
Tf receives and binds iron for delivery to receptors at
recipient cells. Apotransferrin is bilobular and each of
the duplicated lobes binds one atom of Fe(III) and one
carbonate anion to become Tf. This Tf then delivers iron
to cells by binding to TfRs, after which the apotransfer-
rin is returned to the plasma to again function as an iron
transporter (16). The autosomal recessive disorder, clas-
sic hemochromatosis (HH), is most often caused by
mutation in a gene designated HFE on chromosome
6p21.3. It has been shown that the HFE protein com-
petes with Tf for binding to the receptor, thereby imped-
ing the uptake of iron from Tf. Mutation of the HFE
gene abolishes this competition, thereby increasing the
access of Tf and its iron to cells (17).
Iron uptake by cells is essential for cellular growth and
proliferation and is mainly carried out via TfR. TfR1
has been studied extensively (18) while the role of TfR2
is not clear (19). TfR1 mediates the uptake of Tf-bound
iron and remains the major regulatory site for iron
homeostasis (20,21). When iron-loaded Tf attaches to
TfR1, this interaction triggers clathrin-mediated invagi-
nation of the cell membrane and formation of intracellu-
lar Tf-TfR1-containing endosomes. The proton pumps
present in the endosomal membrane pumps H+ ions into
the endosome from the cytoplasm, which induces a con-
formational change of Tf and its receptor resulting in the
release of iron. The released Fe3+ is converted to Fe2+
by STEAP3, a metalloreductase present in the endo-
somes (22,23). The Fe2+ is then transported out of the
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endosomes by DMT1. Human TfR1 expression is regu-
lated by altering the mRNA stability (24) or by the bind-
ing of HFE (25), and also by hypoxia (26). Erythroid
cells contain the highest number of TfRs which are
released from reticulocytes during their maturation to
erythrocytes (27). Human TfR shedding is caused by an
integral membrane metalloprotease releasing a soluble
form, soluble TfR (sTfR) into the plasma. This process
is controlled by Tf (28) and the level of sTfR is an indi-
cator of available functional iron, independent of the
iron stores.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
has been identified on the macrophage cell surface where
it acts as a novel TfR. The GAPDH–Tf complex is sub-
sequently internalized into the endosomes. Iron depletion
increases the expression of GAPDH on the cell surface
(29).
There is compelling evidence that although, under nor-
mal circumstances, Tf-bound iron uptake is the predomi-
nant form of iron uptake by cells, there are alternative
mechanisms of iron transport. In normal individuals, the
plasma concentration of non-Tf-bound iron (NTBI) is
extremely small (30–32). A candidate iron transport pro-
tein has been identified in the brush border cells of the
small intestine (33). Recently, TfR2 in CHO cells and
Zip14 (Slc39a14) in HEK 293H cells and Sf9 insect cells
have been identified as transporters of NTBI. (34,35).
DMT1 has also been implicated in transport of NTBI.
Penetration of NTBI into mitochondria from cytosol
occurs very rapidly and is resistant to high-affinity iron-
binding chelators (36).
Other iron uptake mechanisms also exist. Calcium
channels also act as transporters of iron into cardio-
myocytes under iron-overloaded conditions (37). A
member of the lipocalin super family (24p3 ⁄Ngal) deliv-
ers iron to the cytoplasm where it activates or represses
iron-responsive genes during organogenesis (38). Protein
bound forms of iron such as isoferritin (39) and hemo-
globin can be taken up by the cells. Hemoglobin
released by intravascular hemolysis is bound by hapto-
globin and then taken up by the scavenger receptor
(CD163) present on monocytes and macrophages (40).
Studies have identified H-ferritin as an iron transport
protein and suggest the presence of an H-ferritin recep-
tor for mediating iron delivery in brain and multiple
organs (41). The presence of different iron uptake mech-
anisms helps in accommodating different forms of iron
and also aids in differential regulation. Macrophages
acquire iron from old senescent RBCs which at the end
of their functional lifetime are phagocytosed and catab-
olized at extra vascular sites by Kupffer cells and
splenic macrophages.
Ferritin is an ubiquitous, water soluble protein for
iron storage. The level of serum ferritin parallels the
concentration of storage iron within the body, regardless
of the cell type in which it is stored. Normally, 95% of
the stored iron in liver tissue is found in hepatocytes as
ferritin. Hemosiderin constitutes the remaining 5% and
is found predominately in Kupffer cell lysosomal rem-
nants. Ferritin expression is regulated mainly at the post-
transcriptional level by iron regulatory proteins (IRP1
and IRP2) (42). Pro-oxidants induce the expression of
ferritin H subunit through an antioxidant ⁄ electrophile
response element (43).
Iron and mitochondria
Although excess iron is stored in the cytoplasm, most
of the metabolically active iron is processed in the mito-
chondria of the cell for the synthesis of iron-sulfur clus-
ters (Fe-S) and heme. Little is known about how these
organelles regulate iron homeostasis and toxicity. Data
obtained from studies using yeast strains show that iron
delivery is mediated through Mrs3 ⁄ 4p found in the
inner membrane of mitochondria in yeast (44). Knock
out models of Mrs3 ⁄ 4p revealed that there may be
additional routes. A human homolog of Mrs3 ⁄ 4p has
been identified (45). Studies from a zebra fish mutant,
frascati helped to identify mitoferrin, which functions as
a principal iron importer in vertebrate erythroblasts
(46). Recently it has been shown that the endosomes
come in contact with mitochondria and facilitate direct
transfer of the metal from cytosol to mitochondria (47).
Once inside the mitochondria, iron can be used for a
variety of metabolic pathways. Frataxin, a mitochon-
drial matrix protein enhances the bioavailability of iron
for Fe-S cluster biosynthesis and heme synthesis (48,49).
It is also postulated to play a role in iron export and
storage (50). The mitochondrial ferritin (MtF) acts as
the storage site. MtF has a high degree of sequence
homology with human H-chain ferritin. MtF and cellu-
lar ferritin reveal striking differences in their iron oxida-
tion and hydrolysis chemistry despite their similar
ferroxidase centers (51). Experimental over expression
of MtF results in mitochondrial iron accumulation,
decreased cellular ferritin, and increased TfR1 expres-
sion. MtF plays a protective role against iron mediated
toxicity in the mitochondria. Export of heme from
mitochondria is through an unknown transporter,
whereas the [Fe-S] clusters may be exported to the
cytosol via the mitochondrial inner membrane trans-
porter, ABCB7 (52). The ATP-binding cassette trans-
porter (ABCB6) present in the outer mitochondrial
membrane has also been associated with iron homeo-
stasis and porphyrin transport (53,54). It is proposed
that an Fe-S protein may act as a sensor of mitochon-
drial iron status. Iron transport into mitochondria is
directly coupled to its uptake at the cell membrane
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and iron transport out of mitochondria depends on
adequate iron–sulfur cluster synthesis. Regulatory
mechanisms in the cytosol would then sense a postmi-
tochondrial iron pool (55). Defects in mitochondrial
Fe-S cluster assembly and export can also affect iron
uptake in mitochondria (56). GTP in the mitochondrial
matrix is also involved in the mitochondrial iron
homeostasis. Mutations in the GTP ⁄GDP carrier pro-
tein Ggc1p, results in accumulation of iron within
mitochondria (57).
Regulation of iron homeostasis
The major pathways and the key players involved in iron
absorption, transport and storage have been illustrated
(Fig. 1). Cellular and systemic iron imbalance is detri-
mental and so these processes require a tight regulation.
As iron cannot be effectively excreted, regulation is
mainly at the absorption level. A tight control of iron
homeostasis is also imperative as resistance to infection
is in part dependant on the outcome of a tug-of-war over
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Figure 1 Proteins and pathways involved in non-heme iron absorption, transport and storage, (A) Non-heme iron in the food exists mainly in the
Fe3+ state. It is first reduced to the bio-available Fe2+ state by duodenal cytochrome b reductase and dietary components before it is transported
inside the enterocyte by divalent metal transporter (DMT1). Inside the cell it can be stored as ferritin or transported out with the help of ferropor-
tin (FPN). Heme iron enters the cell through a heme carrier protein. Inside the cell it is opened up by heme oxygenase-1 and the released Fe2+
takes a similar path as of non-heme iron. The Fe2+ leaves the enterocyte through FPN and it is again oxidized to Fe3+ by Hephaestin before being
bound by transferrin (Tf) and transported to different tissues. (B) The storage site of iron is the liver. The Tf-bound iron is taken up by transferrin
receptors (TfR) present on the cell surface. Excess iron is stored as ferritin in the hepatocytes. The mechanism of transport of non-Tf-bound iron
into the hepatocytes remains obscure although several pathways have been hypothesized. The storage iron is released in times of iron require-
ment by hydrolysis of ferritin to yield Fe2+ ions. The Fe2+ is converted to Fe3+ by ceruloplasmin before it is transported by Tf. (C) The majority of
iron is utilized by erythroid cells which take up Tf-bound iron via TfR 1. The TfR are endocytosed and Tf-bound iron is released due to a change in
pH inside the endosomes. The released Fe3+ is converted to Fe2+ by STEAP3. The Fe2+ is transported out of the endosomes by DMT1. Fe2+ is
transported to mitochondria for heme synthesis, a crucial step for Hb formation. (D) Macrophages engulf senescent RBCs and recirculate the iron.
The hemoglobin released is cleaved into heme and globin. The heme molecule is degraded and Fe2+ is transported out by DMT1. The Fe2+
released can be stored either as ferritin or transported out through FPN depending on the iron stores. In circulation, iron (Fe3+) is bound to Tf.
Each Tf molecule can bind two molecules of Fe3+. Ceruloplasmin helps in the oxidation of Fe2+ to Fe3+ and facilitates the transport of iron
released from macrophages and hepatocytes.
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iron between the host and the invading bacteria. This
dual challenge of avoiding iron deficiency and iron over-
load involves distinct regulatory mechanisms to achieve
iron homeostasis both at the cellular and systemic levels.
Regulation of cellular iron homeostasis
Cellular iron homeostasis depends on co-ordinated regu-
lation of proteins involved in iron uptake, storage, utili-
zation and export. Cells react to iron deficiency by up
regulating TfRs to maximize internalization of Tf-bound
iron. Conversely, synthesis of iron storage protein is
halted to enhance metal availability. Intracellular iron
metabolism is mainly controlled at the post-transcrip-
tional level by the iron-responsive elements (IRE) ⁄ IRP
system and this remains the best characterized system of
post-transcription gene expression (58).
Post-transcriptional regulation of intracellular iron lev-
els involves interaction between transacting IRP and
structural motifs known as IRE. These are found in the
mRNAs encoding proteins which are involved in storage,
erythroid heme synthesis, the TCA cycle, iron export and
iron uptake. IREs were first identified in the 5¢-UTR of
ferritin H- and L-chain mRNAs and were noted to medi-
ate inhibition of ferritin mRNA in iron deprived cells
(59). The formation of IRE–IRP complexes in the 5¢-
UTR results in inhibition of the translation process
because of proximity of the IRE to the transcription
start site (60). IRE ⁄ IRP complexes in such cases act as
steric inhibitors of 43 S preinitiation complex binding.
Alternatively the interaction between IRP and IRE in
the 3¢-UTR results in stabilization of the mRNA of the
TfR1. In iron deficient cells the IREs become targets for
the IRPs which bind to them with high affinity resulting
in stabilization of the unstable TfR1 mRNA and transla-
tional inhibition of mRNAs coding ferritin chains. This
enables the cells to increase the uptake of Tf-bound iron
by TfR and minimize sequestration into ferritin. Con-
versely, in cells with enough iron, the IRE ⁄ IRP interac-
tion fails resulting in decreased iron uptake and
increased storage.
IRPs exist in two isoforms – IRP1 and IRP2 that
share extensive sequence homology and belong to the
family of iron–sulfur cluster isomerases (61). IRP-1 and
IRP-2 exhibit similar high affinities for wild type IREs
and are strongly induced in iron deficient cells with rapid
loss of IRE binding after iron administration (62). IRP1
is ubiquitously expressed and this may also be the case
with IRP2. IRPs may be regulated by effectors other
than the cytoplasmic labile iron pool resulting in modu-
lation of cellular iron metabolism. Reactive oxygen spe-
cies and serine phosphorylation (of IRP1) can lead to
disassembly of Fe-S clusters leading to IRP1 regulation
(63,64). Nitric oxide and hypoxia can affect both IRPs
(65). The complex regulation of IRPs by environmental
stimuli at the post-translational level in turn results in
fine tuning of important metabolic pathways in the
human body. IRPs have evolved in such a way that they
sense and control cellular iron levels so as to maintain
the critical balance between ensuring adequate iron sup-
ply and avoiding toxic iron excess (66).
In addition to post-transcriptional modifications in
iron-related genes, cytokines also play a major role in
cellular iron homeostasis. Cytokines like tumor necrosis
factor-a, interleukein-1, interleukin-6 and interferon-c
stimulate H-ferritin and TfR1 expression (67,68). The
finding of IREs in two duodenal transport proteins,
FPN and DMT1 strongly suggests that the IRE ⁄ IRP
regulatory system may have a role in systemic iron regu-
lation (69). IRP1) ⁄ ) mice have a mild phenotype suggest-
ing that IRP2 can fully compensate for the loss of IRP1
function. IRP2) ⁄ ) mice however develop a neurodegener-
ative phenotype secondary to iron overload (70).
Regulation of systemic iron homeostasis
Systemic regulators control iron entry and mobilization
from the stores to fulfill the erythropoietic needs and to
scavenge the previously used iron. Iron balance is main-
tained by meticulous regulation of iron absorption
because of the paucity of well developed regulated path-
ways for iron excretion. Based on segregation of iron
requirements within an organism, several ‘regulators’ for
iron homeostasis have been hypothesized. Iron absorp-
tion is modulated by the amount of iron consumed in
the diet, a mechanism referred to as the ‘dietary’ regula-
tor (71). This phenomenon was previously called the
‘mucosal block’. A second regulatory mechanism termed
the ‘stores’ regulator, senses iron level in the circulation
and responds to the total amount of body iron (72). The
‘stores’ regulator may involve regulation at the level of
crypt programming and facilitates a slow accumulation
of non-heme iron rather than heme-iron. As this regula-
tor must signal between the liver, muscle and intestine a
soluble component is hypothesized. A third regulatory
mechanism, that modulates iron absorption in response
to the erythropoietic demands, is known as the ‘erythro-
poietic’ regulator. The ‘erythropoietic’ regulator is a
stronger inducer of iron absorption in comparison to the
‘stores’ regulator (72). Iron absorption is increased in
response to acute hypoxia through a humoral ‘hypoxia’
regulator. Whether this regulatory pathway is truly dis-
tinct from the one induced by the erythropoietic regula-
tor is uncertain. Cellular iron retention in a setting of
infection and ⁄or inflammation may be a mechanism to
withhold a nutrient from an invading organism. Such
iron accumulation in macrophages may be considered as
an ‘inflammatory’ regulator under normal circumstances.
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The different regulators need not be different and may
represent differential responses mediated by the same
molecules (73). The search for regulatory effectors that
modulate iron absorption and release from tissue stores
has made considerable progress with the identification of
genes involved in hemochromatosis (HFE, TfR2, and
HJV) and the discovery of hepcidin. Hepcidin (HAMP,
LEAP) is thought to be the central regulator of
iron homeostasis and acts as a final point for all other
regulators.
Hepcidin which is secreted by the liver and excreted by
the kidneys appears to be the central regulator of iron
metabolism (74,75). It is also produced in small amounts
by inflammatory monocytes and macrophages (76). Syn-
thesis of hepcidin is greatly stimulated by inflammation
and iron overload (dietary and parenteral) as shown in
murine models (77,78). Based on USF-2 gene knockout
models hepcidin is believed to be the predominant nega-
tive regulator of iron absorption in the small intestine
and iron release from the macrophage (79). Transgenic
mice constructed to over-express hepcidin died shortly
after birth with iron deficiency, indicating that hepcidin
was a negative regulator of placental transport of iron to
the fetus (80). Hepcidin acts on the iron exporter of the
enterocytes and macrophages and suppresses iron uptake
and iron release (81). It also inhibits DMT1 expression
(82). Hepcidin expression is influenced by a variety of
factors and molecules – hypoxia, erythroid demand, iron,
inflammation, copper deficiency, bone morphogenic pro-
teins (BMP), and p53. Erythropoietic demand suppresses
hepcidin expression and GDF 15 is thought to play a
key role in this (15).
HFE, HJV and TFR2 are upstream modulators of
hepcidin. The discovery that HFE was associated with
the TfR was the first indication that HFE may regulate
iron metabolism (83). HFE-associated hereditary HH has
been described as a disorder of enterocyte iron regulation
wherein there is an increase in the iron regulatory set
point resulting in chronic increase in the rate of iron
transfer from enterocyte to blood. It is postulated that
HFE interacts with a protein in a signal transduction
pathway that stimulates hepcidin (84,85). HFE’s role in
regulating iron balance remains enigmatic and more
investigations are required to elucidate the exact mecha-
nism.
Hemojuvelin (HJV) is an important upstream regula-
tor of hepcidin which was discovered recently. The role
of HJV in iron homeostasis has been confirmed by
knockout models, which manifest increased iron deposi-
tion in liver, pancreas and heart (86). Mutated HJV sup-
presses hepcidin expression and this has been observed in
both juvenile HH patients and in HJV) ⁄ ) mice (87,88).
Recent studies indicate that HJV alters hepcidin expres-
sion through a BMP-mediated signaling pathway (89).
BMPs bind to HJV as co-receptors and regulate the tran-
scription of hepcidin through SMAD ⁄SMAD4 complexes
(90).
Unlike TfR1, the role of TfR2 is not clearly eluci-
dated. It also binds ferric-Tf but plays a major role in
systemic iron homeostasis. It is highly expressed in liver
and mutations in this gene result in HH (91). As disrup-
tion of TFR2 causes decreased hepcidin production, it
appears to be involved in the upstream regulation of
hepcidin. Increased serum Tf saturation results in the
release of HFE from HFE–TfR1 complex and binding to
TFR2. This initiates a cascade signaling which results in
the production of hepcidin. Mutation or absence of HFE
or TFR2 affects this signal cascade leading to dysregula-
tion of systemic iron homeostasis (92).
Applied aspects – understanding human disease
The advances in iron metabolism and regulation have
revolutionized the understanding of the molecular basis
of iron related diseases and may lead to the identification
of potential therapeutic targets and novel treatment strat-
egies. Animal models have contributed greatly in under-
standing human diseases of iron metabolism. (Table 1).
Anemia of chronic disease
Anemia of inflammation or anemia of chronic disease
(ACD), is commonly observed in patients with chronic
infections, malignancy, trauma, and inflammatory disor-
ders, and is a well-known clinical entity. It is character-
ized by low serum iron levels (hypoferremia), low serum
iron-binding capacity and normal to elevated ferritin
concentrations. ACD is immune driven and iron homeo-
stasis is altered by cytokines and cells of the reticuloen-
dothelial system. Myeloid cells, when challenged by
bacterial pathogens, produce hepcidin in a TLR4 (toll-
like receptor 4)-dependent manner. Hepcidin expression
is induced by lipopolysaccharide and interleukin-6 and is
inhibited by TNF-a (93). Hepcidin is involved in the
diversion of iron and acts as a link between iron homeo-
stasis and inflammation. It reduces iron absorption and
release from macrophages, thereby reducing iron supply
for erythropoiesis. It decreases iron absorption and iron
release from the macrophages. Bacterial stimulation also
triggers a TLR4-dependent reduction in the expression of
FPN (76). IL-6, a cytokine released during inflammation
mediates the release of hepcidin through STAT3 (94,95).
TNF-a, another cytokine, causes iron sequestration in
the spleen, reduces duodenal iron transfer by increasing
ferritin levels in the enterocyte and leads to loss of func-
tion of FPN in mice (96). HJV is also thought to act in
concert with hepcidin in the pathophysiology of ACD
(97).
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Hemochromatosis
Hemochromatosis refers to a clinical disorder of iron
excess resulting in end organ damage. The disease manifes-
tations include cirrhosis, diabetes mellitus, hypogonadism,
cardiomyopathy, and arthropathy and skin pigmentation.
Identification of genes which are mutated has resulted in
the introduction of molecular tests that allow early and
presymptomatic diagnosis. HH is a genetically hetero-
geneous disorder and may result from mutations in at least
four genes. In the first three, systemic hepcidin deficiency
is the major pathogenetic mechanism.
Mutations in the HFE gene are responsible for type 1
HH and this accounts for more than 90% of patients
with HH. C282Y and H63D are the two most common
mutations observed in population screening (98). The
C282Y mutation replaces a cysteine, required for a disul-
fide bridge, which is necessary for the binding of HFE to
b2-microglobulin (99). The HFE) ⁄ ) mice exhibit pro-
found abnormalities in iron homeostasis. The abnormally
high Tf saturations and excessive accumulation of iron in
liver, seen even on a standard diet, demonstrate that the
HFE gene is a key regulator of iron homeostasis. Emerg-
ing data relate HFE to hepcidin activation in liver. Hep-
cidin levels are inappropriately low for the level of iron
overload in HFE HH (100). In one study, variable levels
of hepcidin ranging to almost normal values in serum
and urine were found in HFE-HH patients. The reason
remains unknown (101).
Juvenile HH (type 2) is a recessive iron overload disor-
der where hypogonadism and cardiac failure are more
frequent presenting symptoms. It results from mutations
in the HJV (type 2A) gene or the gene coding for hepci-
din, HAMP (type 2B) (102,103). However, the common-
est gene involved, however is the HJV gene on the long
arm of chromosome 1. The clinical picture of TfR2 HH
(type 3) is more severe than HFE related HH and has an
earlier age of presentation. TfR2 senses the body iron
status by sensing saturation of Tf (104). TfR2 protein
may also be involved in the erythroid regulator pathway.
FPN (SCL40A1) – FPN Disease (type 4) is a domi-
nant form of iron overload characterized by iron
Table 1 Animal models associated with iron metabolism and their corresponding human phenotypes
Animal model Human disease Gene Phenotype Reference
HFE) ⁄ ), HFEC282Y ⁄ C282Y Hemochromatosis (type 1) HFE Hepatocellular iron deposition
decreased macrophage iron,
elevated Tf saturation and ferritin
(126)
Hepc 1) ⁄ ) Juvenile hemochromatosis HAMP Hepatocellular iron deposition
Decreased macrophage iron
(127)
Hjv) ⁄ ) Juvenile hemochromatosis HJV Hepatocellular iron deposition
Decreased macrophage iron
Elevated Tf saturation
(87)
TfR2) ⁄ ) hemochromatosis (type 3) TFR2 Hepatocellular iron deposition
Decreased macrophage iron
Elevated Tf saturation
(128)
Weh (zebra fish) ND Ferroportin Hypochromic anemia, impaired iron
transfer from yolk sac to embryo
(5)
Nm 1054 ND Not known Hypochromic microcytic anemia
Failure to thrive, infertility
Hydrocephaly
(121)
hpx Atransferrinemia TFR Microcytic hypochromic anemia
Tissue iron deposition
(129, 130)
TfR+ ⁄ ) Chianti (zebra fish) ND TFR1 Microcytic hypochromic RBCs
Decreased iron stores
(114, 131)
Belgrade rat Iron deficiency anemia with
tissue iron overload
DMT1 Systemic iron deficiency, impaired
iron uptake in duodenum and
erythroid precursors
Hepatic iron overload
(132)
Shiraz (zebra fish) ND Grx5 Anemia, loss of iron cluster assembly (123)
Cp) ⁄ ) Aceruloplasminemia Cp Iron accumulation in hepatocyte
and macrophages
(133)
sla mouse ND HEPH Microcytic hypochromic anemia (122)
Frda– tissue specific
k.o neuron ⁄ heart
Friedreich ataxia Frataxin Mitochondrial iron deposits,
neurodegeneration, cardiomyopathy
(134)
Hemoglobin deficit mouse ND Sec15l1 Microcytic hypochromic anemia (135)
ND, not described.
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accumulation in the macrophages but low ⁄normal Tf sat-
uration. Heterozygous mutations of the SCL40A1, the
gene encoding FPN, have been documented (105,106).
FPN mutants may reach the membrane but are resistant
to the action of hepcidin, resulting in hepcidin resistance,
and a HH like phenotype (107).
Rare genetic defects of iron loading and iron
deficiency
There are rare genetic conditions leading to iron defi-
ciency and iron overload in the tissues that pose diagnos-
tic and therapeutic difficulties (Table 2). Divalent metal
transporter is responsible for iron transport at the brush
border of the enterocyte and from endosomes to cytosol.
Mutations in DMT1 are a rare cause for iron deficiency
and overload. Iron deficiency is caused by defective
absorption while iron overload may be related to the
upregulation of the heme iron absorption pathway that
bypasses the DMT1 defect. Both mk mice and Belgrade
rats, which carry an identical DMT1 mutation (G185R),
exhibit severe microcytic anemia at birth, defective intes-
tinal iron absorption and erythroid iron utilization.
Mutations in DMT1 in humans are characterized by
hypochromic microcytic anemia and hepatic iron over-
load. The first case of homozygous DMT1 mutation
(1285G > C exon 12 skipping) in humans has been
reported recently. The patient had hypochromic microcy-
tic anemia with significant hepatic iron overload (108).
Another novel mutation, described subsequently, is a
3bp deletion in intron 4 (c.310–315delCTT) resulting in a
splicing abnormality and a C fi T transition at nucleo-
tide 1246(p. R416C) (109). Two more reports of DMT1
mutations have also been published (110,111).
Another gene identified in iron refractory iron defi-
ciency anemia is TMPRSS6. It encodes a type II trans-
membrane serine protease which is produced by the liver
and regulates the expression of the systemic iron regula-
tory hormone, hepcidin. It is essential for normal sys-
temic iron homeostasis in humans. Mutations in this
gene have been associated with iron deficiency anemia
refractory to iron. The key features are: a congenital
hypochromic, microcytic anemia; a low Tf saturation;
abnormal iron absorption, characterized by no hemato-
logical improvement following treatment with oral iron;
abnormal iron utilization characterized by a sluggish,
incomplete response to parenteral iron (112) .
Hypotransferrinemia is a rare recessive disease charac-
terized by an extremely low Tf level (<10 mg ⁄L), severe
iron deficiency anemia and iron loading of the liver and
other non-erythroid organs (113). This condition empha-
sizes the importance of the Tf-TfR1 pathway for ery-
throid iron uptake. Alternative pathways for
internalization of non-Tf-bound iron result in the iron
overload. Extremely low hepcidin levels in the hypo-
transferrinemic mouse hpx explain the increased intesti-
nal iron absorption. Low hepcidin may be secondary to
anemia or lack of TfR2 signaling (104) . Tf replacement
by plasma transfusion is the treatment of choice in these
patients.
The Tf cycle is essential for iron uptake. Homozygous
TfR mutant mice die between 9.5 and 11.5 d postconcep-
tion. Heterozygote mutants present with microcytosis
though they are not anemic (114). This interesting phe-
notype suggests that some humans with unexplained
microcytosis may be heterozygous for TfR1 gene muta-
tions.
Aceruloplasminemia is a rare autosomal recessive dis-
order resulting from deficiency of the ferroxidase activity
of ceruloplasmin that is responsible along with FPN for
iron export out of the macrophage and hepatocytes. The
Table 2 Rare causes of iron deficiency and iron overload in humans
Gene Inheritance Defect Findings Reference
DMT1 Autosomal recessive Iron deficiency anemia Hypochromic microcytic anemia
Hepatic iron overload
(108–111)
Tf Autosomal recessive Hypotransferrinemia Severe iron deficiency anemia
Iron loading of the liver
Low hepcidin levels
(113)
TfR Autosomal
recessive
Heterozygous for TfR1 mutation Microcytosis (136)
Cp Autosomal recessive Aceruloplasminemia Anemia
Diabetes mellitus
Iron loading of liver, pancreas
Neurological and retinal degeneration
(115)
ABCB7 X-linked X-linked sideroblastic anemia with ataxia Anemia
Iron accumulation in mitochondria
(116, 117)
TMPRSS6 Iron refractory iron deficiency anemia (112)
DMT1, divalent metal transporter; TfR, transferrin receptor.
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disease is characterized by diabetes mellitus, iron loading
of the liver and pancreas and neurological and retinal
degeneration (115). Mild anemia is present in early life.
Serum iron and Tf saturation are low but elevated ferri-
tin should raise the suspicion. Murine models indicate
that the iron excess may be related to defective cellular
iron flux.
Defects in ABCB7, a transporter which is responsible
for transport of iron and Fe-S clusters from mitochon-
dria, causes X-linked sideroblastic anemia with ataxia
(116,117). This is characterized by iron accumulation in
the mitochondria, iron which is therefore not available
for heme synthesis. Mutations in the Frataxin gene are
responsible for mitochondrial iron deposits, neurodegen-
eration and cardiomyopathy in Friedreich ataxia (118).
A functional deficiency of frataxin affects intracellular
iron distribution and Fe-S cluster biogenesis.
The hemoglobin deficit mouse, suffers from a micro-
cytic, hypochromic anemia and exhibits a defective iron
transport in the endocytosis cycle. An exon deletion in
the candidate gene Sec15l1, a key protein in vesicle dock-
ing has been described as the cause of defective endo-
cytosis (119,120). A recessive, hypochromic, microcytic
anemia mouse mutant, nm1054 has been reported. It is
caused by an intrinsic hematopoietic defect, resulting in
inefficient Tf-dependent iron uptake by erythroid precur-
sors (121).
Sex-linked sla mice, carry mutations in the hephaestin
gene-ferrous oxidase, which along with FPN is responsi-
ble for basolateral iron transport (122). These mice are
anemic at birth because of defective placental iron trans-
fer. The anemia disappears with age though low iron
stores persist. These two mutations have not been
described in humans.
The hypochromic anemia in shiraz (sir) zebrafish
mutants is caused by deficiency of glutaredoxin 5 (grx5),
a gene required in yeast for Fe-S cluster assembly (123).
Loss of Fe-S cluster assembly activates IRP1 and blocks
heme biosynthesis leading to anemia.
The constellation of microcytic anemia, increased tis-
sue iron deposition, and neurodegeneration has been
documented in IRP2-deficient mice. Here, the iron lim-
ited erythropoiesis is because of reduced TfR expression
in erythroid precursors (124). Hyperferritinemia-cataract
syndrome is caused by a heterozygous mutation of the
IRE of L-ferritin resulting in deregulated synthesis of fer-
ritin. The only pathological consequence appears to be
early cataract (125). The pathogenesis of neonatal iron
overload and reticuloendothelial iron overload in Afri-
can-American individuals (described initially in Bantu
population) is as yet unknown.
Recent advances in identifying specific proteins
involved in iron metabolism and their regulation have
provided glimpses of the elaborate inter-connected cir-
cuitry operational in the human body. These new
insights have had a major impact in understanding the
pathophysiology of iron-related genetic disorders. How-
ever, the urgent need is to further our understanding of
intestinal iron absorption at the molecular level and how
it is linked to cellular iron balance. Polymorphisms in
many of these genes may underlie individual susceptibil-
ity to both iron deficiency and iron overload in the pres-
ence of environmental excess or decreased availability of
iron. New molecules to treat iron overload are urgently
required, both for genetic and acquired disorders, where
iron overload has devastating consequences and they
may be developed earlier because of this new under-
standing of the players which regulate iron homeostasis
in the body.
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